General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Diabetes Mellitus, Type 2 with high cardiovascular risk
Last updated April 13, 2016
Trajenta/Jentaduo (linagliptin (linagliptin/metformin))
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Diabetes Mellitus, Type 2
Last updated April 12, 2016
Prezcobix (darunavir/cobicistat)
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
HIV-1 Infection
Last updated March 24, 2016
Status:
Concluded without agreement
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Chronic Hepatitis C
Last updated March 17, 2016
Inspiolto Respimat (tiotropium/olodaterol)
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Heart failure, NYHA class II
Last updated March 2, 2016
Spiriva Respimat (tiotropium bromide)
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated March 2, 2016
Status:
Concluded with an LOI
Manufacturer:
Lupin Pharma Canada Ltd.
Indication:
Hepatic Encephalopathy
Last updated March 2, 2016
Status:
Concluded without agreement
Manufacturer:
Alexion Pharma Canada Corp.
Indication:
Atypical hemolytic uremic syndrome
Last updated February 16, 2016
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Metastatic Melanoma
Last updated February 10, 2016
Januvia (sitagliptin phosphate)
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated February 8, 2016